Impact of adherence and highly active antiretroviral therapy on survival in HIV-infected patients.

Objectives: To assess the effect of antiretroviral therapy (ART) adherence on survival in HIV-infected patients. Design: Cohort study at a single hospital in Barcelona, Spain. Methods: Data on HIV-infected patients older than 18 years of age who began ART during the period 1990 to 1999 were analyzed. Patients were considered nonadherent if the total dose of antiretroviral drug was less than 90% of that prescribed. Adherence was assessed through self-report and hospital pharmacy appointments. Cox regression with time-dependent variables was used. Results: A total of 1219 patients were included. The first ART was with monotherapy in 23.7% of cases, with two drugs in 30.5%, and with triple therapy in 45.8%. In multivariate analysis, the variables that presented significant differences with respect to mortality were clinical stage at the beginning of treatment (AIDS: relative hazard (RH) = 2.97; 95% confidence interval [CI]: 2.14-4.13), CD4 cell count (<200 cells/μL: RH = 5.89; CI: 3.44-10.10), type of treatment (monotherapy: RH = 9.76; Cl: 4.56-20.90; bi-therapy: RH = 9.12; CI: 4.23-19.64), and adherence (nonadherence: RH = 3.87; CI: 1.77-8.46). Conclusions: The modifiable factors most strongly associated with survival were type of treatment and adherence. It would be desirable to accompany therapy with intervention strategies intended to improve adherence.

[1]  A. Wu,et al.  Patient-reported nonadherence to HAART is related to protease inhibitor levels. , 2000 .

[2]  A. Phillips,et al.  Factors affecting survival in patients with the acquired immunodeficiency syndrome. , 1996, AIDS.

[3]  G. Sirera,et al.  Mortality of HIV-positive and HIV-negative heroin abusers as a function of duration of injecting drug use. , 2000 .

[4]  J. Darbyshire,et al.  Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals , 1996, The Lancet.

[5]  M. T. Paixão,et al.  Expanded European AIDS case definition , 1993, The Lancet.

[6]  J. Margolick,et al.  Immunologic and virologic response to highly active antiretroviral therapy in the Multicenter AIDS Cohort Study , 2001, AIDS.

[7]  D. Vlahov,et al.  Impact of HIV infection on non‐AIDS mortality among Italian injecting drug users , 1994, AIDS.

[8]  J. Pitt,et al.  Selective vertical transmission of HIV‐1 antiretroviral resistance mutations , 1998, AIDS.

[9]  R. Salamon,et al.  Clinical, biologic, and behavioral predictors of early immunologic and virologic response in HIV-infected patients initiating protease inhibitors. , 2001 .

[10]  D. Costagliola,et al.  'Do HIV-infected injecting drug users over-report adherence to highly active antiretroviral therapy?' A comparison between patients' self-reports and serum protease inhibitor concentrations in the French Manif 2000 cohort study. , 2001, AIDS.

[11]  Barbara Turner,et al.  Improving on a Coin Toss To Predict Patient Adherence to Medications , 2001, Annals of Internal Medicine.

[12]  Douglas Richman,et al.  Viral Dynamics of HIV: Implications for Drug Development and Therapeutic Strategies , 1996, Annals of Internal Medicine.

[13]  M. Sprangers,et al.  Limited patient adherence to highly active antiretroviral therapy for HIV-1 infection in an observational cohort study. , 2001, Archives of internal medicine.

[14]  M. Fletcher,et al.  Disease progression, adherence, and response to protease inhibitor therapy for HIV infection in an Urban Veterans Affairs Medical Center. , 1999, Journal of acquired immune deficiency syndromes.

[15]  D Johnson,et al.  The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response. California Collaborative Treatment Group. , 1999, AIDS.

[16]  JD Lundgren,et al.  Changing patterns of mortality across Europe in patients infected with HIV-1 , 1998, The Lancet.

[17]  R. Coutinho,et al.  Predictors of mortality in the Amsterdam cohort of human immunodeficiency virus (HIV)-positive and HIV-negative drug users. , 1996, American journal of epidemiology.

[18]  P. Tsasis,et al.  Adherence assessment to highly active antiretroviral therapy. , 2001, AIDS patient care and STDs.

[19]  J. Rockstroh,et al.  Reply: Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients. , 1997, AIDS.

[20]  B. Clotet,et al.  Quantitative HIV-1 RNA as a marker of clinical stability and survival in a cohort of 302 patients with a mean CD4 cell count of 300 x 10(6)/l. , 1996, AIDS.

[21]  A. Mocroft,et al.  Regional survival differences across Europe in HIV-positive people: the EuroSIDA study. , 1999, AIDS.

[22]  Amalio Telenti,et al.  CD4-cell count in HIV-1-infected individuals remaining viraemic with highly active antiretroviral therapy (HAART) , 1998, The Lancet.

[23]  A. Zolopa,et al.  Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. , 2001, AIDS.

[24]  J. Montaner,et al.  A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study. , 1998, JAMA.

[25]  A. Wu,et al.  Adherence to antiretroviral and pneumocystis prophylaxis in HIV disease. , 1998, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[26]  S. Hammer,et al.  Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel. , 2000, JAMA.

[27]  Ann Marie Swart,et al.  Concorde: MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection , 1994, The Lancet.

[28]  Susan Swindells,et al.  Adherence to Protease Inhibitor Therapy and Outcomes in Patients with HIV Infection , 2000, Annals of Internal Medicine.

[29]  R. Hays,et al.  Measuring Adherence to Antiretroviral Medications in Clinical Trials , 2000, HIV clinical trials.